ArQule is a personalized medicine company working in the oncology space to develop treatments that target specific mutations. The Massachusetts-based company faces many challenges in this space, including one that is common to many cancer treatments.
Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions.
One Watertown, Mass.-based biotech is working to capitalize on growing momentum for cell and gene therapies — and it seems to have found its opening. The company is working on a technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell. [...]
Patrik De Haes, MD, CEO of Oxurion, discusses the company’s three disease-modifying drug candidates for the treatment of diabetic eye disease with EyeWire News at the Ophthalmology Innovation Summit in Chicago.
Arena’s run of positive news continues, with a massive $800 million upfront licensing deal with United Therapeutics for its pulmonary arterial hypertension drug ralinepag. The global deal, which also includes $400 million in milestones and double-digit royalties, comes on the heels of well-regarded phase 2 data with the oral prostacyclin receptor agonist in PAH that caused [...]
A $238,000 federal study will follow more than 10,000 medical marijuana patients in New York over the next two years to see if their opioid use drops. Scott Jordan never thought weed would help him kick the painkillers he took for a bad back. “I smoked pot in high school,” he told BuzzFeed News. [...]
Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment. Arena Pharma said the money will help it prepare for the eventual launch of its bowel disorder drugs. [...]
United Therapeutics $UTHR is paying an $800 million cash upfront in a big bet to stay among the leaders in pulmonary arterial hypertension, grabbing rights to Arena Pharmaceuticals’ ralinepag in the deal. And the executive crew is willing to add hundreds of millions more in milestones if they can stay on track through to an approval and commercialization. [...]
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Quantum Genomics’ blood pressure drug firibastat, an inhibitor that targets aminopeptidase A in the brain, met its primary endpoint in a phase 2b study—which the company says paves the way for a wider phase 3 trial in more resistant hypertension.
See author Cormac Sheridan's discussion of the biotech industry members developing therapeutics based on targeting the Wnt pathway in this issue of Nature Biotech. Included in the report is Samumed, a company developing a Wnt-targeted therapy for the treatment of Osteoarthritis and other prevalent diseases.
A small-molecule intra-articular Wnt pathway inhibitor, SM04690, is being developed and the results of a phase IIb trial were presented at the ACR meeting by Yusuf Yazici, MD, of NYU Langone School of Medicine in New York City and Samumed, LLC, in San Diego.
Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.
CHICAGO: At the Ophthalmology Innovation Summit at AAO, Patrik De Haes, MD, CEO of Oxurion, introduces the company’s new clinical portfolio with three separate molecules in clinical trials for the treatment of diabetic macular edema.
“For Celyad, the sequence of listing first in Europe and then in the US allowed the company to first strengthen and solidify its company and clinical roots in Europe, and then broaden its investor base and support new programs by listing in the US,” Filippo Petti, CFO of Celyad, told me.
We recently spoke to Alexis Peyroles, CEO at OSE Immunotherapeutics to hear more about the findings of their recent study, published in Nature Communications, describing, for the first time ever, the in vivo mechanism of action of interleukin 7 receptor alpha (IL-7Rα) monoclonal antibodies, suggesting therapeutic efficacy in controlling chronic inflammation.
Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration.
Researchers are testing a new transdermal patch from Zosano Pharma that could deliver treatment for migraines.
Taking medical cannabis led 62 percent of patients with chronic nerve pain to cut down or stop their opioid use, according to a first-of-its-kind pilot study that tracked 76 individuals over nine months.
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness. The plan is to start a phase 1/2 trial of the drug in 2019.
At the 2018 American Academy of Ophthalmology Annual Meeting in Chicago, IL, Patrik De Haes, MD, CEO of Oxurion (formerly ThromboGenics) spoke about several investigational molecules his company is investigating for various retina conditions.
Columbia Care is the largest multi-state medical cannabis operator in the United States. With a total of 33 licenses in 13 states, the company is looking to make an impact in the global cannabis industry by partnering with Canaccord Genuity Growth. Nicholas Vita, CEO and co-founder of Columbia Care, joins Cheddar to discuss. [...]
Nicholas Vita, Columbia Care CEO, discusses how Canada's legalization of recreational marijuana on Wednesday will affect the medicinal use market and how it may influence U.S.-based regulations.
Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa.
Krystal Biotech (KRYS) rocketed to a record high Monday after its gene therapy showed promise as a skin disease treatment. In midday trading on the stock market today, Krystal stock soared 30.9%, near 20.50. Earlier, Krystal popped as much as 37.6% in higher-than-average volume. Krystal stock began trading around 10 in September 2017.
In a game-changing preclinical study targeted toward controlling graft-versus-host disease (GvHD), OSE Immunotherapeutics SA has shown new efficacy results evaluating FR104 and whether a transplant takes. This study, announced Aug. 22, showed strong evidence in the value of targeting CD28 in GvHD for potential clinical applications in autoimmune diseases and transplantation.
Dr. Nolan Williams, Clinical Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University. We speak about new treatment options for use in treatment-resistant patients with OCD, including brain stimulation. A deep TMS device was recently FDA approved for the treatment of treatment-resistant OCD.
Two years after Arrowhead Pharmaceuticals $ARWR conceded that a substantial segment of their RNAi pipeline was hopelessly compromised and had to be jettisoned, crippling their stock price, the biotech is staging a major comeback.
Arena announced encouraging data from a small Phase IIa study for oloranib (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.
Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and ulcerative colitis. According to CEO Hartmut Ehrlich, ABX464 binds the human cap binding complex (CBC) and promotes its splicing [...]
